Coherus’ Pegfilgrastim Sales Fall $150m In 2021 As Firm Plans On-Body

Pegfilgrastim Revenues Set To Slide Again In 2022 Amid Challenging Market

 
• By Dean Rudge

Coherus BioSciences has posted a massive loss for 2021 due to tumbling revenues, as well as continued investment in its pipeline projects, not least the proposed on-body injector device for its pegfilgrastim biosimilar alongside a ranibizumab asset.

A Businessperson Stopping Colorful Dominoes From Falling On Desk
Coherus is aiming to stop falling sales with new launches • Source: Alamy/Andriy Popov

More from Earnings

More from Business